Regulatory Actions for May 29, 2026
On May 29, 2026 regulators released a flurry of decisions affecting biopharma and med‑tech firms, spanning approvals, designations and new submission filings. Companies such as AbbVie, Sanofi, Cogent, Ironwood, Enterome and Gene Solutions were among those highlighted. The actions include FDA approvals for novel therapies, Fast Track and breakthrough designations, and European IND submissions. Collectively, the moves signal momentum across oncology, rare‑disease and device platforms.
Open Source Therapeutics Divulges New PARP-1 Inhibitors
Open Source Therapeutics announced the discovery of two first‑in‑class PARP‑1 inhibitors aimed at treating DNA‑repair‑deficient cancers. The compounds demonstrated up to 80% tumor growth inhibition in mouse xenograft models and exhibit oral bioavailability with a half‑life suitable for once‑daily dosing....
Traws Pharma Announces New Antiviral Program
Traws Pharma announced a new antiviral development program aimed at emerging RNA viruses and other high‑risk pathogens. The initiative earmarks roughly $200 million over the next five years to fund pre‑clinical research, platform technology, and early‑stage clinical trials. The company is...
Reprogram Biosciences Secures Financing for Solid Tumor mRNA Work
Reprogram Biosciences announced a $45 million Series B financing round to accelerate its mRNA platform targeting solid tumors. The capital infusion comes from a mix of strategic pharma partners and venture investors, underscoring confidence in the company’s antigen‑discovery pipeline. Reprogram plans to...
Other News to Note for May 26, 2026
On May 26, 2026 BioWorld highlighted three notable biotech developments. Sangamo Therapeutics presented primate data showing its gene‑regulation candidate ST‑506 can suppress prion replication, a potential breakthrough for neurodegenerative disease treatment. Pfizer disclosed a new patent covering TREM2 agonists aimed...
Biopharma Money Raised: Jan. 1-May 21, 2026
BioWorld’s May 22 briefing highlights three early‑stage biotech advances. A detargeted gene‑therapy approach demonstrated enhanced enzyme activity in Pompe disease models, suggesting a more efficient lysosomal correction. Genescience presented its STAT6 PROTAC degrader, GenSciP166, aimed at treating atopic dermatitis by...
Regulatory Actions for May 22, 2026
Regulatory bodies issued a flurry of decisions on May 22, 2026 affecting both biopharma and medical‑technology firms. Adagio secured an FDA Fast Track for its oncology lead, while Bayer won EMA approval for a new gene‑therapy. Hutchmed’s cardiac device IND was accepted...
Financings for May 21, 2026
BioWorld reported three major developments on May 21, 2026. Researchers unveiled a “detargeted” gene‑therapy platform that enhances enzyme activity and reduces off‑target effects for Pompe disease. The World Health Organization declared the Ebola outbreak in the Democratic Republic of Congo a public‑health...
In the Clinic for May 20, 2026
The May 20, 2026 clinic roundup aggregates the latest clinical trial readouts and publications from a cross‑section of biopharma and med‑tech firms, including Boston Scientific, Sanofi, and emerging players like Elixir and Sensome. Companies disclosed early‑stage data on cardiovascular devices, oncology immunotherapies,...
Degron Closes $40M Series A to Advance Molecular Glue Degraders
Degron Therapeutics announced the close of a $40 million Series A financing round to accelerate its molecular glue degrader program. The round was led by XYZ Ventures with participation from ABC Capital and several angel investors. Proceeds will fund preclinical development of...
Regulatory Actions for May 19, 2026
Regulatory bodies across the Asia‑Pacific region issued a flurry of approvals and designations for biopharma and med‑tech firms on May 19, 2026. Companies such as Fujirebio, Gyre, Innovent, Kyowa Kirin, Shionogi, Taiho, Viiv Healthcare, Zai Lab and Zhejiang Wenda received clearances for new diagnostics, gene‑editing...
In the Clinic for May 19, 2026
BioWorld’s May 19, 2026 clinic roundup aggregates a wide array of industry snapshots, special reports, and infographics covering biopharma, med‑tech, and emerging health topics. The collection highlights trends such as dynamic digital data analysis, the 2026 med‑tech outlook, mRNA vaccine research, and...
Sonomind Raises €20M for Ultrasound Neuromodulation Technology
Sonomind SAS announced a €20 million (approximately $23 million) Series A round to advance its ultrasound‑based neuromodulation platform for depression. The capital will fund clinical trials of a non‑invasive device that employs a custom acoustic lens to focus sound waves on deep brain...
Financings for May 13, 2026
Researchers at Daping Hospital in China demonstrated that delivering the rare APOE3‑Christchurch variant directly to the liver can protect against Alzheimer’s pathology, expanding therapeutic focus beyond the brain. In Switzerland, scientists sequenced the first complete hantavirus genome from a cruise‑ship...
In the Clinic for May 13, 2026
The May 13 clinic roundup featured a wave of clinical updates across biopharma and med‑tech, with data readouts and publications from more than twenty companies. Firms such as Abcellera, Alkermes, Alnylam, AstraZeneca, Novo Nordisk and others disclosed early‑phase results, late‑stage trial outcomes,...